Development and in vitro evaluation of magnetic/hybrid nanostructured lipid carriers as a tool for targeted delivery of anticancer drugs

RODENAK B; NOACCO N; PEREZ DE BERTI N; CRESPO R; CASTRO, G. R.; LEON I.E; ISLAN, G.A.

Congreso; LXIII Reunión Científica Anual de la Sociedad Argentina de Investigación Clínica, LXII Reunión Anual de la Sociedad Argentina de Inmunologia (SAIC-SAI-SAFIS); 2019

Cancer is the second cause of death in the world and many of the current therapies arestill ineffective or present highly toxic side effects. Nanostructured lipid carriers (NLC)are nanosized colloidal drug-delivery systems composed of a binary solid/liquid lipidscore and functionalizable surface developed for the encapsulation of lipophiliccompounds in order to improve the stability, bioavailability, controlled release andselective targeting of therapeutic drugs. Here, we designed biocompatible hybridchitosan (Chi) coated NLC containing the monoterpene 1,8-cineole (CN), acting as bothbioactive molecule and nanostructuring liquid lipid, and magnetic nanoparticles (MNP),as a smart system for drug delivery to cancer cells. NLC, NLC/Chi and NLC/Chi/MNPnanoparticles (NPs) were prepared by ultrasonication. NPs were characterized bydetermining particle size, surface charge (SC), magnetic behavior, encapsulationefficiency (EE) and kinetic release of CN. Cell viability and cellular uptake of NPs wereevaluated in human liver (HepG2) and lung (A549) cancer cells, and normal lung (WI38)cells.NPspresentedsphericalshape,sizesintherangeof190-270nmwithnarrowdistribution,andSCof-2.0mV(NLC),+7.0mV(NLC/Chi)y+10.0mV(NLC/Chi/MNP).MNPandNLC/Chi/MNPshowedmagneticresponsewithsaturationmomentsof79and60emu/g Fe, respectively. The EE of CN in all NPs was greater than 77% and theyshowed biphasic CN release profile. CN-loaded NPs inhibited up to 73.6% (A549) and77.2% (HepG2) cancer cells viability (p